Taking advantage of a large-scale NCI drug-screening program assessing sensitivity of the NCI60 cancer cell line panel to several thousand compounds including > 200 known DNA-damaging agents50, we correlated macroH2A1.1 expression with sensitivity to 72 TOP1 inhibitors in the breast cancer subset. Here, TOP1 is linked to breast carcinoma.